Evidence map›Paper›PMID 38540148›Full record

ArticleBiomedicines2024

Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes.

Urska Janzic, Andrej Janzic, Abed Agbarya, Urska Bidovec-Stojkovic, Katja Mohorcic, Marina Caks, Peter Korosec, Matija Rijavec, Erik Skof

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Urska JanzicDepartment of Medical Oncology, University Clinic Golnik, 4204 Golnik, Slovenia.ORCID 0000-0001-9232-1431
Andrej JanzicFaculty of Medicine, University of Maribor, 2000 Maribor, Slovenia.
Abed AgbaryaBnai-Zion Medical Center, Oncology Institute, Haifa 31048, Israel.ORCID 0000-0002-3330-2959
Urska Bidovec-StojkovicLaboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia.ORCID 0000-0001-8978-6887
Katja MohorcicDepartment of Medical Oncology, University Clinic Golnik, 4204 Golnik, Slovenia.
Marina CaksDepartment of Oncology, University Medical Centre Maribor, 2000 Maribor, Slovenia.
Peter KorosecLaboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia.
Matija RijavecLaboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia.ORCID 0000-0002-2596-4952
Erik SkofMedical Faculty Ljubljana, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0001-7076-4186
University of Ljubljana · SIUniversity Clinic of Pulmonary and Allergic Diseases Golnik · SIBnai Zion Medical Center · ILUniversity Clinical Centre Maribor · SIUniversity of Maribor · SI

Funding

Slovenian Research Agency P3-0360
6 · The paper itself

Abstract

Due to the devastating COVID-19 pandemic, a preventive tool in the form of vaccination was introduced. Thoracic cancer patients had one of the highest rates of morbidity and mortality due to COVID-19 disease, but the lack of data about the safety and effectiveness of vaccines in this population triggered studies like ours to explore these parameters in a cancer population. Out of 98 patients with thoracic malignancies vaccinated per protocol, 60-75% experienced some adverse events (AE) after their first or second vaccination, most of them were mild and did not interfere with their daily activities. Out of 17 severe AEs reported, all but one were resolved shortly after vaccination. No significant differences were noted considering AE occurrence between different cancer therapies received after the first or second vaccination dose,

Indexed as

adverse eventsbreakthrough infectioncancer therapyCOVID-19 vaccinationthoracic malignancies

Identifiers

PMID38540148
PMCPMC10968145
OpenAlexW4392188615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.